TNF and inflammatory bowel disease: In the IBD group (n = 87), 9 of 16 patients (56.3%) who used anti-TNF (Tumor necrosis factor) agents were diagnosed with CMV-GID, while 31 of 71 patients (43.7%) who did not use anti-TNF agents were diagnosed with CMV-GID, and the difference was found to be statistically insignificant (P = .361).